Investigating a new RNA that affects immune response in aggressive breast cancer.
Official title: The long non-coding RNA LINC01133 as a novel determinant of immune evasion in triple-negative breast cancer
Funded at VA Boston Health Care System · NIH-11003963 · Data updated 2026-11-12
This study is looking at a type of breast cancer called triple-negative breast cancer, which often affects younger women of African and Latino backgrounds, to see how a specific molecule called LINC01133 might be making the cancer grow and resist treatment, with the goal of finding new ways to help improve care for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Boston Health Care System NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX005980-02 |
| Project ID | NIH-11003963 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are younger women of African and Latino descent diagnosed with triple-negative breast cancer.
✕Less likely to help
Patients with other types of breast cancer or those who do not have triple-negative breast cancer may not benefit from this research.
What this research studies
This research focuses on triple-negative breast cancer (TNBC), a particularly aggressive form of cancer that primarily affects younger women of African and Latino descent. The study aims to understand the role of a specific long non-coding RNA, LINC01133, which has been found to promote cancer growth and resistance to treatment. By analyzing tumor cells and their interactions with the immune system, the researchers hope to identify new therapeutic targets that could improve treatment outcomes for patients. The approach includes using anti-sense oligonucleotides to inhibit LINC01133 and assess its impact on cancer cell growth and immune response.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that enhance the immune response against triple-negative breast cancer.
How similar studies have gone: Previous research has shown promise in targeting long non-coding RNAs for cancer treatment, suggesting potential success for this novel approach.
Where this research is happening
-
VA Boston Health Care System
Boston, United States Active
Researchers
- Principal investigator: Karnoub, Antoine Elias — VA Boston Health Care System
- Study coordinator: Karnoub, Antoine Elias
Related research
Other NIH-funded projects on the same topics.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
A new peptide therapy to help treat metastatic triple-negative breast cancer
A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.